ATE66372T1 - Mikropartikel, bestehend aus einem biodegradierbaren, die freisetzung eines antimalaria-wirkstoffs kontrollierenden polymer, diese enthaltende pharmazeutische zusammensetzungen und ihr herstellungsverfahren. - Google Patents

Mikropartikel, bestehend aus einem biodegradierbaren, die freisetzung eines antimalaria-wirkstoffs kontrollierenden polymer, diese enthaltende pharmazeutische zusammensetzungen und ihr herstellungsverfahren.

Info

Publication number
ATE66372T1
ATE66372T1 AT88401965T AT88401965T ATE66372T1 AT E66372 T1 ATE66372 T1 AT E66372T1 AT 88401965 T AT88401965 T AT 88401965T AT 88401965 T AT88401965 T AT 88401965T AT E66372 T1 ATE66372 T1 AT E66372T1
Authority
AT
Austria
Prior art keywords
microparticles
release
pharmaceutical compositions
compositions containing
biodegradable polymer
Prior art date
Application number
AT88401965T
Other languages
English (en)
Inventor
Jose Bontemps
Philippe Pirson
Jean-Bernard Falmagne
Robert Jerome
Philippe Teyssie
Luc Delattre
Brigitte Evrard
Original Assignee
Wallone Region
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wallone Region filed Critical Wallone Region
Application granted granted Critical
Publication of ATE66372T1 publication Critical patent/ATE66372T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT88401965T 1987-07-30 1988-07-28 Mikropartikel, bestehend aus einem biodegradierbaren, die freisetzung eines antimalaria-wirkstoffs kontrollierenden polymer, diese enthaltende pharmazeutische zusammensetzungen und ihr herstellungsverfahren. ATE66372T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8710802A FR2618674B1 (fr) 1987-07-30 1987-07-30 Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
EP88401965A EP0301969B1 (de) 1987-07-30 1988-07-28 Mikropartikel, bestehend aus einem biodegradierbaren, die Freisetzung eines Antimalaria-Wirkstoffs kontrollierenden Polymer, diese enthaltende pharmazeutische Zusammensetzungen und ihr Herstellungsverfahren

Publications (1)

Publication Number Publication Date
ATE66372T1 true ATE66372T1 (de) 1991-09-15

Family

ID=9353715

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88401965T ATE66372T1 (de) 1987-07-30 1988-07-28 Mikropartikel, bestehend aus einem biodegradierbaren, die freisetzung eines antimalaria-wirkstoffs kontrollierenden polymer, diese enthaltende pharmazeutische zusammensetzungen und ihr herstellungsverfahren.

Country Status (9)

Country Link
US (1) US4897267A (de)
EP (1) EP0301969B1 (de)
JP (1) JPS6442433A (de)
AT (1) ATE66372T1 (de)
CA (1) CA1329549C (de)
DE (1) DE3864348D1 (de)
ES (1) ES2024668B3 (de)
FR (1) FR2618674B1 (de)
GR (1) GR3002601T3 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2644462B1 (fr) * 1988-09-23 1993-07-09 Ire Celltarg Sa Nouveaux composes actifs sur les formes tissulaires de la malaria et procede de preparation
LU87410A1 (fr) * 1988-12-20 1990-07-10 Cird Composition cosmetique ou pharmaceutique contenant des microspheres de polymeres ou de corps gras chargees d'au moins un produit actif
FR2659554B1 (fr) 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US5610753A (en) * 1991-12-12 1997-03-11 Eastman Kodak Company Optical design of laser scanner to reduce thermal sensitivity
ZA93929B (en) * 1992-02-18 1993-09-10 Akzo Nv A process for the preparation of biologically active materialcontaining polymeric microcapsules.
US5514378A (en) * 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US6689608B1 (en) 1993-02-01 2004-02-10 Massachusetts Institute Of Technology Porous biodegradable polymeric materials for cell transplantation
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
FR2764514B1 (fr) 1997-06-13 1999-09-03 Biopharmex Holding Sa Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique
US6306425B1 (en) 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
WO2001015699A1 (en) 1999-08-27 2001-03-08 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
CN1194704C (zh) * 2001-11-12 2005-03-30 华东理工大学 含有活性药物、主链中具有氨基酸的聚酯及其制备方法
ATE493116T1 (de) * 2004-01-21 2011-01-15 Univ London Pharmacy Verfahren zur herstellung von mikroteilchen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL263733A (de) * 1960-04-19 1900-01-01
BE755975A (fr) * 1969-09-10 1971-03-10 Dann Otto Nouveaux derives de la quinoleine, compositions pharmaceutiquesen contenant et leur obtention
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3663552A (en) * 1970-04-09 1972-05-16 American Home Prod 2'-substituted-cinchona alkaloids
DE2748333A1 (de) * 1977-10-28 1979-05-03 Hoechst Ag Mittel gegen malaria
US4416872A (en) * 1982-03-17 1983-11-22 The United States Of America As Represented By The Secretary Of The Army Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates
CA1196864A (en) * 1983-06-10 1985-11-19 Mattheus F.A. Goosen Controlled release of injectable and implantable insulin compositions

Also Published As

Publication number Publication date
FR2618674A1 (fr) 1989-02-03
EP0301969B1 (de) 1991-08-21
JPS6442433A (en) 1989-02-14
FR2618674B1 (fr) 1990-06-15
US4897267A (en) 1990-01-30
CA1329549C (fr) 1994-05-17
ES2024668B3 (es) 1992-03-01
DE3864348D1 (de) 1991-09-26
GR3002601T3 (en) 1993-01-25
EP0301969A1 (de) 1989-02-01

Similar Documents

Publication Publication Date Title
ATE66372T1 (de) Mikropartikel, bestehend aus einem biodegradierbaren, die freisetzung eines antimalaria-wirkstoffs kontrollierenden polymer, diese enthaltende pharmazeutische zusammensetzungen und ihr herstellungsverfahren.
JP3934684B2 (ja) 徐放製剤
AU2002216042B2 (en) Freeze-dried pantoprazole preparation and pantoprazole injection
KR880013553A (ko) 개선된 상 분리 마이크로캡슐화 방법 및 그로부터 제조된 제약학적 조성물
EP1968638B1 (de) Gele mit kontrollierter wirkstofffreisetzung
CN102666511B (zh) 甲基锍氯化物结晶水合物
KR880004802A (ko) 서방성(徐放性) 입자 제제 및 이의 제조방법
EP0947194A1 (de) Darreichungsformen enthaltend feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
EP0427247A2 (de) Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
US11020410B2 (en) Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
ATE5852T1 (de) Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
DE4338508A1 (de) Arzneimittelzubereitungen enthaltend Thioctsäure oder Dihydroliponsäure in Form von Einschlußverbindungen mit Cyclodextrinen oder Cyclodextrinderivaten und in Form von Granulaten, Kau- oder Brausetabletten
EP1535916B1 (de) Einschlusskomplexe aus butylphthalid und cyclodextrin derivaten und verfahren zu deren herstellung
KR910009665A (ko) 메일라아드 반응의 억제를 위한 제약조성물 및 방법
KR880009018A (ko) 3-l-피로글루타밀-l-티아졸리딘-4-카르복실산 및 이의 제법
CN104817592A (zh) 金合欢素的水溶性衍生物和前药及其制备和使用方法
FR2613223B1 (fr) Forme galenique se presentant sous la forme de grains hydrosolubles, en particulier a base d'un extrait sec de ginkgo biloba, et son procede de preparation
ATE269352T1 (de) 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung
FR2630647B1 (fr) Microbilles de diltiazem, leur procede de fabrication et compositions pharmaceutiques a liberation prolongee les contenant
KR920006911B1 (ko) 안정한 피록시캄 주사액 조성물 및 그의 제조방법
KR100422418B1 (ko) 불용성 약물의 서방형 제제의 제조방법
OA09379A (fr) Polyméthylène-imines disubstituées, leur procédé de préparation et les compositions pharmaceutiques les contenant.
JPH1017472A (ja) 徐放性抗腫瘍製剤
JPH11512705A (ja) チック症を処置する方法
Riley The prodrug concept and new drug design and development

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee